

May 22, 2024

To

**BSE Limited** 

The Deputy Manager (Listing - CRD), Phiroze Jeejeebhoy Towers, **Dalal Street** Mumbai - 400 001

**Scrip Code**: <u>533151</u>

**ISIN:** INE950I01011

The National Stock Exchange of India Limited

The Manager (Listing Department), Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E)

Mumbai - 400 051 **SYMBOL:** DBCORP

Sub.: Outcome of the Meeting of the Board of Directors of D. B. Corp Limited held on Wednesday, May 22, 2024 in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ["SEBI Listing Regulations"]

Dear Sir/Madam,

Pursuant to the provisions of the SEBI Listing Regulations, we wish to inform you that, the Board of Directors in its Meeting held today i.e. May 22, 2024 has inter alia, approved the following:

#### A. Audited Financial Results:

The Audited Financial Results (Standalone and Consolidated) of the Company for the 4<sup>th</sup> quarter and the financial year ended on March 31, 2024.

#### B. Third Interim Dividend for the Financial Year 2023-24:

Payment of Third Interim Dividend of Rs. 8/- (Rupees only) per Equity Share of face value ('FV') of Rs. 10/- each (i.e. 80% of FV) [subject to Tax Deducted at Source] for the Financial Year 2023-24.

Pursuant to Regulation 42 of the SEBI Listing Regulations, the details of record date for the purpose of payment of third interim dividend are as follows:

BSE Scrip Code	NSE Symbol	Type of Security	Record Date	Purpose	Payment Date
533151	DBCORP	Equity	June 3, 2024	For the purpose of	On or before
		Shares		ascertaining	June 20,
				eligibility of	2024











	shareholders for	
	payment of Third	
	Interim Dividend for	
	F.Y. 2023-24	

## C. Appointment of Senior Management Personnel, Mr. Upendra Kumar Gupta as 'President -Finance & Accounts' of the Company:

On the basis of recommendation of the Nomination and Remuneration Committee, the Board of Directors approved the appointment of Mr. Upendra Kumar Gupta as 'President - Finance & Accounts' of the Company with effect from June 1, 2024. Mr. Upendra Kumar Gupta as 'President - Finance & Accounts' will be categorised as Senior Management Personnel.

Details with respect to the aforesaid appointment as required under Regulation 30 read with Para A(7) of Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 are provided in Annexure A attached herewith.

The meeting of the Board of Directors of the Company commenced at 11.00 a.m. (IST) and concluded at 12.20 p.m. (IST).

This intimation is also being uploaded on the Company's website i.e. www.dbcorpltd.com.

We request you to take this on record, and to treat the same as compliance with the applicable provisions of the SEBI Listing Regulations.

Thanking you.

Yours truly, For D. B. Corp Limited

**Om Prakash Pandey Company Secretary & Compliance Officer** 

Encl.: As above











### Annexure 'A'

# Appointment of Senior Management Personnel, Mr. Upendra Kumar Gupta as 'President -Finance & Accounts' of the Company

Sr. No.	Particulars	Update
1	Reason for change viz. appointment, re-appointment, resignation, cessation, removal, death or otherwise;	The Board of Directors of the Company has today viz. Wednesday, May 22 2024, on the basis of recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. Upendra Kumar Gupta as 'President - Finance & Accounts' of the Company. Mr. Upendra Kumar Gupta as 'President - Finance & Accounts' will be categorised as Senior Management Personnel.
2	Date of appointment/re-appointment/cessation (as applicable) & term of appointment;	June 1, 2024
3	Brief profile (in case of appointment);	Mr. Upendra Kumar Gupta has overall 31 years of experience. He holds a degree of Chartered Accountant, Cost & Management Accountant and Company Secretary. Currently, he is working with Writers and Publishers Private Limited (part of Dainik Bhaskar Group) as President — Finance. Prior to joining Dainik Bhaskar Group, he has worked with Supermax, Videocon, Ranbaxy, Dabur and Procter & Gamble.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not related to any Director or Key Managerial Personnel of the Company.







